Chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving.\nLike other technologies, CAR-T cell therapy has undergone a long development process, and persistent explorations of the\nactions of the intracellular signaling domain and make several improvements have led to the superior efficacy when anti-CD19\nCAR-T cell treatments in B cell cancers. At present, CAR-T cell therapy is developing rapidly, and many clinical trials have been\nestablished on a global scale, which has great commercial potential. This review mainly describes the toxicity of CAR-T cell\ntherapy and the challenges of CAR-T cells in the treatment of solid tumors, and looks forward to future development and\nopportunities for immunotherapy and reviews major breakthroughs in CAR-T cell therapy.
Loading....